TargetSphingosine kinase 1(Homo sapiens (Human))
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: hohno@pharm.kyoto-u.ac.jp.
Curated by ChEMBL
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: hohno@pharm.kyoto-u.ac.jp.
Curated by ChEMBL
Affinity DataKi: 40nMAssay Description:Inhibition of recombinant human SphK1 expressed in baculovirus infected sf9 cells using D-erythro-sphingosine as substrate in presence of [gamma-33P]...More data for this Ligand-Target Pair
TargetSphingosine kinase 2(Homo sapiens (Human))
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: hohno@pharm.kyoto-u.ac.jp.
Curated by ChEMBL
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: hohno@pharm.kyoto-u.ac.jp.
Curated by ChEMBL
Affinity DataKi: 1.20E+3nMAssay Description:Inhibition of recombinant human SphK2 expressed in baculovirus infected sf9 cells using D-erythro-sphingosine as substrate after 20 mins in presence ...More data for this Ligand-Target Pair
TargetSphingosine kinase 1(Homo sapiens (Human))
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: hohno@pharm.kyoto-u.ac.jp.
Curated by ChEMBL
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: hohno@pharm.kyoto-u.ac.jp.
Curated by ChEMBL
Affinity DataKi: >1.00E+4nMAssay Description:Inhibition of recombinant human SphK1 expressed in baculovirus infected sf9 cells using D-erythro-sphingosine as substrate after 20 mins in presence ...More data for this Ligand-Target Pair
TargetSphingosine kinase 2(Mus musculus (Mouse))
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: hohno@pharm.kyoto-u.ac.jp.
Curated by ChEMBL
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: hohno@pharm.kyoto-u.ac.jp.
Curated by ChEMBL
Affinity DataKi: 1.41E+4nMAssay Description:Inhibition of recombinant mouse SphK2 expressed in baculovirus infected sf9 cells using D-erythro-sphingosine as substrate in presence of [gamma-33P]...More data for this Ligand-Target Pair
Affinity DataIC50: 0.784nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 2.20nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 2.20nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 2.30nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 2.60nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetSphingosine kinase 1(Homo sapiens (Human))
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: hohno@pharm.kyoto-u.ac.jp.
Curated by ChEMBL
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: hohno@pharm.kyoto-u.ac.jp.
Curated by ChEMBL
Affinity DataIC50: 2.70nMAssay Description:Inhibition of recombinant C-terminal His6-tagged human SphK1 expressed in baculovirus infected sf21 cells using FITC-sphingosine as substrate after 1...More data for this Ligand-Target Pair
Affinity DataIC50: 2.80nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 2.90nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 3.10nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 3.30nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 3.30nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 3.40nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 3.40nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 3.5nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 3.60nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 3.80nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 4.5nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 4.60nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 4.60nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 5.40nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 5.40nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 8.10nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 21nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 21nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 35nMAssay Description:Displacement of [125I]SDF1 from human CXCR4 expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 39nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 52nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 61nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Taisho Pharmaceutical Co., Ltd.
Curated by ChEMBL
Affinity DataIC50: 86nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 133nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
![](/img/powered_by_small.gif)